It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Spinal disinhibition has been hypothesized to underlie pain hypersensitivity in neuropathic pain. Apparently contradictory mechanisms have been reported, raising questions on the best target to produce analgesia. Here, we show that nerve injury is associated with a reduction in the number of inhibitory synapses in the spinal dorsal horn. Paradoxically, this is accompanied by a BDNF-TrkB-mediated upregulation of synaptic GABAARs and by an α1-to-α2GABAAR subunit switch, providing a mechanistic rationale for the analgesic action of the α2,3GABAAR benzodiazepine-site ligand L838,417 after nerve injury. Yet, we demonstrate that impaired Cl- extrusion underlies the failure of L838,417 to induce analgesia at high doses due to a resulting collapse in Cl- gradient, dramatically limiting the benzodiazepine therapeutic window. In turn, enhancing KCC2 activity not only potentiated L838,417-induced analgesia, it rescued its analgesic potential at high doses, revealing a novel strategy for analgesia in pathological pain, by combined targeting of the appropriate GABAAR-subtypes and restoring Cl- homeostasis.
Disinhibition in the dorsal horn of the spinal cord may contribute to chronic pain. Here the authors show that, despite a paradoxical increase in α2/α3 subunits of the GABAA receptor in a neuropathic pain model, inhibition eventually fails due to KCC2 hypofunction.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details





1 Quebec Mental Health Institute, CERVO Brain Research Centre, Québec, Canada; McGill University, Department of Pharmacology & Therapeutics, Montreal, Canada (GRID:grid.14709.3b) (ISNI:0000 0004 1936 8649)
2 Quebec Mental Health Institute, CERVO Brain Research Centre, Québec, Canada (GRID:grid.14709.3b); Université Laval, Department of Psychiatry & Neuroscience, Québec, Canada (GRID:grid.23856.3a) (ISNI:0000 0004 1936 8390); Université Laval, Graduate program in Neuroscience, Québec, Canada (GRID:grid.23856.3a) (ISNI:0000 0004 1936 8390)
3 Quebec Mental Health Institute, CERVO Brain Research Centre, Québec, Canada (GRID:grid.23856.3a); Université Laval, Department of Psychiatry & Neuroscience, Québec, Canada (GRID:grid.23856.3a) (ISNI:0000 0004 1936 8390); Université Laval, Graduate program in Neuroscience, Québec, Canada (GRID:grid.23856.3a) (ISNI:0000 0004 1936 8390); University of Turin, Department of Veterinary Sciences, Turin, Italy (GRID:grid.7605.4) (ISNI:0000 0001 2336 6580)
4 Quebec Mental Health Institute, CERVO Brain Research Centre, Québec, Canada (GRID:grid.7605.4)
5 Quebec Mental Health Institute, CERVO Brain Research Centre, Québec, Canada (GRID:grid.7605.4); Université Laval, Graduate program in Neuroscience, Québec, Canada (GRID:grid.23856.3a) (ISNI:0000 0004 1936 8390)
6 Quebec Mental Health Institute, CERVO Brain Research Centre, Québec, Canada (GRID:grid.23856.3a)
7 Quebec Mental Health Institute, CERVO Brain Research Centre, Québec, Canada (GRID:grid.23856.3a); IP Paris, Ecole Polytechnique, Palaiseau, France (GRID:grid.23856.3a)
8 Quebec Mental Health Institute, CERVO Brain Research Centre, Québec, Canada (GRID:grid.23856.3a); Université Laval, Graduate program in Neuroscience, Québec, Canada (GRID:grid.23856.3a) (ISNI:0000 0004 1936 8390)
9 Chlorion Pharma, Laval, Québec, Canada (GRID:grid.23856.3a) (ISNI:0000 0004 1936 8390); Laurent Pharmaceuticals Inc., Montreal, Canada (GRID:grid.23856.3a)
10 Quebec Mental Health Institute, CERVO Brain Research Centre, Québec, Canada (GRID:grid.23856.3a); University of Otago, Centre for Innovation, Dunedin, New Zealand (GRID:grid.29980.3a) (ISNI:0000 0004 1936 7830)
11 Quebec Mental Health Institute, CERVO Brain Research Centre, Québec, Canada (GRID:grid.29980.3a); Université Laval, Finite Element Interdisciplinary Research Group (GIREF), Québec, Canada (GRID:grid.23856.3a) (ISNI:0000 0004 1936 8390)
12 McGill University, Department of Pharmacology & Therapeutics, Montreal, Canada (GRID:grid.14709.3b) (ISNI:0000 0004 1936 8649); McGill University, Department of Anatomy & Cell Biology, Montreal, Canada (GRID:grid.14709.3b) (ISNI:0000 0004 1936 8649); McGill University, Alan Edwards Centre for Research on Pain, Montreal, Canada (GRID:grid.14709.3b) (ISNI:0000 0004 1936 8649)
13 Quebec Mental Health Institute, CERVO Brain Research Centre, Québec, Canada (GRID:grid.14709.3b); McGill University, Department of Pharmacology & Therapeutics, Montreal, Canada (GRID:grid.14709.3b) (ISNI:0000 0004 1936 8649); Université Laval, Department of Psychiatry & Neuroscience, Québec, Canada (GRID:grid.23856.3a) (ISNI:0000 0004 1936 8390); Université Laval, Graduate program in Neuroscience, Québec, Canada (GRID:grid.23856.3a) (ISNI:0000 0004 1936 8390); McGill University, Alan Edwards Centre for Research on Pain, Montreal, Canada (GRID:grid.14709.3b) (ISNI:0000 0004 1936 8649)